02:21 , Jan 5, 2016 |  BC Extra  |  Company News

Management tracks

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN), which is developing complement factor D ( CFD ; adipsin ) inhibitors for ultra-rare diseases, named Joel Barrish CSO. He was VP and head of discovery chemistry at Bristol-Myers Squibb Co....
08:00 , Nov 10, 2014 |  BC Week In Review  |  Clinical News

ARA 290 regulatory update

FDA granted Fast Track designation to Araim's ARA 290 to treat sarcoidosis-associated small fiber neuropathy. The short tissue protective peptide is in Phase IIb testing for the indication, with Phase III testing slated for 4Q15....
07:00 , Oct 28, 2013 |  BC Week In Review  |  Clinical News

ARA 290 regulatory update

The European Commission granted Orphan Drug designation to Araim's ARA 290 to treat sarcoidosis. The short tissue protective peptide is in Phase IIb testing for small fiber neuropathy in sarcoidosis patients and Phase IIa testing...
08:00 , Feb 21, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Dermatology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Dermatology Burns Erythropoietin (EPO); colony stimulating factor 2 receptor-b low-affinity (CSF2RB; CD131) Mouse studies suggest an EPO mimetic could help treat burns....
00:04 , Sep 30, 2011 |  BC Extra  |  Company News

BARDA awards up to $70.7M for radiation therapies

HHS's Biomedical Advanced Research and Development Authority awarded five contracts worth up to a total of $70.7 million for the development of therapies to treat acute radiation injuries. Araim Pharmaceuticals Inc. (Ossining, N.Y.) received $3.1...
08:00 , Jan 13, 2011 |  BC Innovations  |  Targets & Mechanisms

EPO plays defense

North American researchers have shown that erythropoietin can stave off the destruction of pancreatic islet b cells in mouse models of type 1 and type 2 diabetes. 1 Although erythropoietin itself is unlikely to become...